Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
OLMA Stock Chart & Stats
$22.56
$0.55(10.50%)
At close: 4:00 PM EST
$22.56
$0.55(10.50%)
Day’s Range― - ―
52-Week Range$2.86 - $36.26
Previous CloseN/A
Volume1.27M
Average Volume (3M)1.21M
Market Cap
$1.77B
Enterprise Value$1.74B
Total Cash (Recent Filing)$328.96M
Total Debt (Recent Filing)$4.48M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding78,659,920
10 Day Avg. Volume1,184,457
30 Day Avg. Volume1,213,037
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)0.84
Price to Sales (P/S)0.00
P/FCF Ratio-3.28
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.62K
Enterprise Value/Ebitda-10.81
Forecast
1Y Price Target
$45.78Price Target Upside102.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.21
Revenue Forecast (FY)$2.05M
Bulls Say, Bears Say
Bulls Say
Analyst Sentiment And Catalyst VisibilityAnalyst Buy and Overweight ratings combined with an active catalyst watch increase investor focus on upcoming trial readouts and may attract capital into OLMA shares.
Competitor Phase 3 ReadthroughPositive Phase 3 results for a competitor's oral SERD that reduced invasive disease recurrence support readthrough to palazestrant and could raise expectations for OLMA's late-stage program.
Drug Differentiation And Combination AdvantagePalazestrant's differentiated pharmacology and demonstrated safety when paired with ribociclib suggest a potential efficacy and tolerability advantage versus competing regimens, supporting a stronger commercial profile.
Bears Say
Analyst Rating And Volatility RiskA Buy/High Risk analyst rating highlights elevated share-price volatility and the potential for sharp downside if trial news or competitor developments disappoint market expectations.
Clinical Endpoint RiskFailure to show clear progression-free or overall survival benefits would undermine claims of palazestrant's superiority and could apply substantial downward pressure on the stock.
Trial Enrollment RiskDemonstrating benefit in patients without the ESR1 resistance mutation depends on enrolling sufficient numbers of those patients, creating a meaningful enrollment and execution risk for pivotal studies.
Olema Pharmaceuticals News
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $2.86 and its highest was $36.26 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Olema Pharmaceuticals’s market cap is $1.77B.
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is May 12, 2026 which is in 66 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 78,659,920 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Currently, no hedge funds are holding shares in OLMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Olema Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.78 (102.93% Upside)
$45.78 (102.93% Upside)
Blogger Sentiment
Bullish
OLMA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $24.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
479.52%
12-Months-Change
Fundamentals
Return on Equity
-59.22%
Trailing 12-Months
Asset Growth
53.13%
Trailing 12-Months
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
OLMA Stock 12 Month Forecast
Average Price Target
$45.78
▲(102.93% Upside)
Technical Analysis
Meiragtx Holdings
―
Arvinas Holding Company
―
Gossamer Bio
―
Keros Therapeutics
―
Compass Therapeutics
―
Ownership Overview
Currently, No data available
---